Innate Pharma (IPHA) Current Assets (2017 - 2025)

Innate Pharma (IPHA) has disclosed Current Assets for 8 consecutive years, with $91.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Assets fell 42.47% year-over-year to $91.6 million, compared with a TTM value of $91.6 million through Dec 2024, down 42.47%, and an annual FY2024 reading of $92.8 million, down 42.04% over the prior year.
  • Current Assets was $91.6 million for Q4 2024 at Innate Pharma, down from $159.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $206.8 million in Q4 2020 and bottomed at $91.6 million in Q4 2024.
  • Average Current Assets over 5 years is $151.7 million, with a median of $158.2 million recorded in 2021.
  • The sharpest move saw Current Assets increased 11.63% in 2023, then plummeted 42.47% in 2024.
  • Year by year, Current Assets stood at $206.8 million in 2020, then decreased by 23.52% to $158.2 million in 2021, then dropped by 9.8% to $142.7 million in 2022, then rose by 11.63% to $159.3 million in 2023, then tumbled by 42.47% to $91.6 million in 2024.
  • Business Quant data shows Current Assets for IPHA at $91.6 million in Q4 2024, $159.3 million in Q4 2023, and $142.7 million in Q4 2022.